NCT06943677 - A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Advanced Malignant Cancer

Interventions

DRUG

TQB3019 capsules

TQB3019 capsule is a targeted protein degrader

Trial Locations (5)

NOT_YET_RECRUITING

The Cancer Hospital Affiliated to Shandong First Medical University, Jinan

NOT_YET_RECRUITING

Institute of Hematology ＆Blood Diseases Hospital,Chinese Academy of Medical Sciences ＆Peking Union Medical College, Tianjin

RECRUITING

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Mianyang Central Hospital, Mianyang

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an